Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial

Anchalee Avihingsanon(Chulalongkorn University), Taisheng Li(Peking Union Medical College Hospital), Ellen Koenig(Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz"), Hal Martin(Gilead Sciences (United States)), Khuanchai Supparatpinyo(Chiang Mai University), Fujie Zhang(Capital Medical University), Chien‐Ching Hung(National Taiwan University), Jared M. Baeten(University of Washington), Sasisopin Kiertiburanakul(Ramathibodi Hospital), Jason T. Hindman(Gilead Sciences (United States)), Hongzhou Lu(Southern University of Science and Technology), Hongyuan Wang(Beijing Institute of Technology), Sophia Rahman(Gilead Sciences (United States)), Michelle L. D’Antoni(Gilead Sciences (United States)), Chee Loon Leong, Man‐Po Lee(Queen Elizabeth Hospital)
The Lancet HIV
July 23, 2023
Cited by 62


Related Papers